You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

BEVIRIMAT
(MPC-4326, PA-456)

Myriad Halts Development of HIV Maturation Inhibitor Bevirimat
6/11/2010

Bevirimat (MPC-4326) Resistance Is Common among Treatment-naive and Protease inhibitor-experienced HIV Patients

12/11/09

Myriad Begins Phase 2b Study of HIV Maturation Inhibitor MPC-4326 (Bevirimat) in Genetically-Identified Responders

12/08/09

HIV Maturation Inhibitor Bevirimat Demonstrates Promising Safety and Efficacy in Patients with Responsive HIV Genotype

9/25/09

Newer Anti-HIV Drugs and How to Use Them: Part 2
6/26/09

Experimental HIV Maturation Inhibitor Bevirimat Demonstrates Good Antiviral Activity and Favorable Safety Profile
10/04/08

Panacos Announces Data from Phase 2b Trial of HIV Maturation Inhibitor Bevirimat (PA-457)

3/07/2008

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children